AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 111 min read$CYTK

Landry Robert E sold $75K of CYTK

Landry Robert E sold 1,000 shares of CYTOKINETICS INC (CYTK) at $74.66 on 2026-09-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Landry Robert E
Published Sep 11, 2026, 11:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 11:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CYTK
Neutral
high confidence
Mentioned
$CYTK
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CYTKNeutralLow
01

Why it matters

The sale is routine and unlikely to trigger trading activity, but investors may monitor for patterns in insider behavior.

02

Market read

A modest insider sale with limited market impact; primarily of interest to existing shareholders.

03

What to watch

Potential upcoming clinical trial results or regulatory news not disclosed in the filing.

Relevance 2/10Novelty 4/10Timing: filed today

Background

SEC Form 4 filings disclose insider transactions. Directors often use 10b5-1 plans for scheduled sales.

Company-level read

Ticker impact

$CYTKNeutralHigh confidence
Context

Director Robert E. Landry sold 1,000 CYTK shares for $74.66 each, reducing his stake to 9,184 shares.

Expected impact

Minimal impact; price likely unchanged.

Evidence & confidence

The transaction size (~$75k) is modest for a director and disclosed via a 10b5-1 plan, suggesting routine portfolio rebalancing rather than a red flag.

Market effects

Sector

None; Cytokinetics operates in biotech, and the insider sale is too small to affect sector sentiment.

Regional

None; the filing is U.S.-specific and does not influence broader regional markets.

Global

None; limited to CYTK shareholders.

Counterpoint

What could challenge this read

If the director anticipates upcoming negative news, even a small sale could precede a price decline.

Key entities

  • Company
    Cytokinetics Inc

    Biopharmaceutical company developing cardiac and skeletal muscle therapeutics.

  • Insider
    Robert E. Landry

    Director of Cytokinetics who executed the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CYTK insider trading history →

Related articles

OCT 13
$CYTKHigh

Cytokinetics Highlights Exercise Capacity, Responder Data For Aficamten In NHCM At HFSA 2026

Cytokinetics (CYTK) presented data from the ACACIA-HCM trial at the HFSA 2026 meeting, showing aficamten improved exercise performance and clinical outcomes in non-obstructive HCM patients. The drug demonstrated significant benefits in exercise capacity, symptom relief, and safety, with 53% of patients showing improvements across multiple domains. CYTK reported a Q2 2026 net loss of $198.8M and $25.3M in aficamten revenue, with cash reserves of $1.7B.

rttnews.com2 min
OCT 12
$CYTKMed

Cytokinetics presents additional aficamten data from trial

Cytokinetics (CYTK) presented additional data from its ACACIA-HCM trial at the Heart Failure Society of America Annual Scientific Meeting. Aficamten showed statistically significant improvements in exercise performance and clinical response in patients with non-obstructive hypertrophic cardiomyopathy. The company plans to submit a supplemental New Drug Application to the FDA this quarter for this indication.

uk.investing.com1 min
OCT 12
$CYTKMed

Serious heart failure events affected 4.7% taking aficamten, versus 1.2% on placebo.

Cytokinetics (CYTK) presented additional data from the ACACIA-HCM trial at the HFSA Annual Scientific Meeting. The study showed aficamten improved exercise performance and safety in non-obstructive HCM patients. Serious heart failure events occurred in 4.7% of aficamten patients vs. 1.2% on placebo. The company plans to submit a supplemental New Drug Application to the FDA this quarter.

stocktitan.net4 min